• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune-related adverse events after a single dose of pembrolizumab.

作者信息

Vos Hanne, Lambein Kathleen, Wildiers Hans, Punie Kevin, Smeets Ann

机构信息

Department of Surgical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.

Department of Surgical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.

出版信息

Eur J Cancer. 2021 May;148:92-94. doi: 10.1016/j.ejca.2021.01.048. Epub 2021 Mar 16.

DOI:10.1016/j.ejca.2021.01.048
PMID:33740501
Abstract
摘要

相似文献

1
Immune-related adverse events after a single dose of pembrolizumab.
Eur J Cancer. 2021 May;148:92-94. doi: 10.1016/j.ejca.2021.01.048. Epub 2021 Mar 16.
2
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.帕博利珠单抗单药治疗的长期安全性及其与临床结局的关系：晚期黑色素瘤患者的里程碑式分析。
Eur J Cancer. 2021 Feb;144:182-191. doi: 10.1016/j.ejca.2020.11.010. Epub 2020 Dec 24.
3
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.帕博利珠单抗在 PD-L1 表达≥50%的 NSCLC 大真实世界队列患者中的免疫相关不良事件及其与临床结局的关系。
Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
4
Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.帕博利珠单抗相关癌症患者的致死性不良事件：一项荟萃分析。
Cancer Invest. 2020 Feb;38(2):130-138. doi: 10.1080/07357907.2020.1721521. Epub 2020 Feb 5.
5
Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.一线帕博利珠单抗治疗高 PD-L1 肿瘤表达的晚期或复发性非小细胞肺癌患者的真实世界疗效。
Clin Lung Cancer. 2020 Sep;21(5):e366-e379. doi: 10.1016/j.cllc.2020.02.017. Epub 2020 Feb 26.
6
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.帕博利珠单抗治疗的非小细胞肺癌患者肝功能受损的假象：病例报告。
Anticancer Drugs. 2019 Aug;30(7):e0764. doi: 10.1097/CAD.0000000000000764.
7
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.免疫相关不良反应预测抗 PD-1 抗体在癌症患者中的治疗效果。
Eur J Cancer. 2019 Mar;109:21-27. doi: 10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22.
8
Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.免疫检查点抑制剂治疗晚期非小细胞肺癌患者的超进展性疾病：病例报告及文献复习。
Lung Cancer. 2020 Jan;139:18-21. doi: 10.1016/j.lungcan.2019.10.026. Epub 2019 Oct 31.
9
Pembrolizumab in the Treatment of Breast Cancer.帕博利珠单抗治疗乳腺癌
N Engl J Med. 2022 Jul 21;387(3):273-274. doi: 10.1056/NEJMe2207532.
10
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.

引用本文的文献

1
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.单次剂量免疫检查点阻断后迅速发生的免疫相关不良事件。
J Immunother Cancer. 2025 Sep 23;13(9):e012756. doi: 10.1136/jitc-2025-012756.